Davy James, Associate Editor

Thiopurines found to increase the risk of myeloid disorders.

Researchers seek to get ahead of potential future Ebola outbreaks.

TIM-family proteins may be able to block a wide range of viral infections.

Experimental drug results in 100% recovery in primates up to 5 days following infection.

A protein found in nearly half of African Americans speeds removal of medication from the body.

Experimental drug results in 100% recovery in primates up to 5 days following infection.

Phase I study deems treatment safe and tolerable in humans.

Treatment co-developed by National Institutes of Health and GlaxoSmithKline gets fast-tracked as World Health Organization issues dire prediction.

Phase I study deems treatment safe and tolerable in humans.

Treatment co-developed by National Institutes of Health and GlaxoSmithKline gets fast-tracked as World Health Organization issues dire prediction.

Limitations in available staff and protective equipment put medical personnel at increased risk.

First-in-class treatment option available for severe aplastic anemia patients who had insufficient responses to immunosuppressive therapy.

Limitations in available staff and protective equipment put medical personnel at increased risk.

First-in-class treatment option available for severe aplastic anemia patients who had insufficient responses to immunosuppressive therapy.

Efficacy of treatment still undetermined as World Health Organization raises cost of battle strategy.

Efficacy of treatment still undetermined as World Health Organization raises cost of battle strategy.

A different Ebola strain reported in Congo as researchers race to find a vaccine.

A different Ebola strain reported in the Congo as researchers race to find a vaccine.

Aurora to utilize enhanced therapy management services with Armada's ReachRx Online Therapy Management system.

Ceasing treatment may be the only way to determine whether HIV is cured, but doing so carries long-term risks.

Doctors say experimental drugs should not be limited to well-off patients.

Study finds that ceasing treatment may be the only way to determine if the disease is cured, but doing so carries long-term risks.

Doctors say experimental Ebola drugs should not be limited to well-off patients.

Promising treatment protects nonhuman primates from Marburg virus up to 3 days after infection.

Savings from biosimilars may not offer much relief due to development and manufacturing costs, according to Catamaran report.

Promising treatment protects nonhuman primates from Marburg virus up to 3 days after infection.

Doctors Without Borders said virus cannot be contained without massive mobilization of resources to West Africa.

Genzyme's eliglustat offers long-term treatment for Type 1 Gaucher disease.

The FDA has granted approval to Genzyme's eliglustat (Cerdelga), the only first-line oral therapy for patients with Type 1 Gaucher disease.

Doctors Without Borders says virus cannot be contained without massive mobilization of resources to West Africa.